Treatment Persistence Associated with Typical versus Atypical Antipsychotics among Out-patients with Schizophrenia
Journal Title: Journal of Pharmaceutical Research International - Year 2016, Vol 10, Issue 4
Abstract
Aim: The chronic nature of schizophrenia usually demands uninterrupted treatment in order to maintain optimal clinical and functional outcomes. It has been speculated that patients receiving atypical antipsychotics may persist longer in treatment than those receiving typical antipsychotics because of the lower risk of inducing extra-pyramidal symptoms. This study aimed to compare treatment persistence among patients with schizophrenia receiving atypical versus typical antipsychotics after discharge from a psychiatric hospital in Lagos, south-west Nigeria. Study Design and Methodology: A retrospective cohort study design. Clinical records of 162 patients with schizophrenia admitted to a public psychiatric hospital were extracted to determine their persistence with treatment over a period of one year after their discharge to out-patient clinic. Treatment persistence (time to all cause treatment discontinuation) was determined using the Kaplan-Meier Survival analyses. The log rank test compared persistence in treatment between patients receiving atypical versus typical antipsychotic medications. Results: Only 27.1% persisted in treatment for six months, while 19.1% persisted for one year. The mean time to all cause treatment discontinuation was 17.3 (±1.5) weeks (95% C.I= 14.4-20.3). The mean duration of treatment persistence for patients receiving typical antipsychotics was 16.7 (±2.7) weeks (95% C.I= 11.5-22.0), and 17.7 (±1.8) weeks (95% C.I= 14.2-21.2) for patients receiving atypical antipsychotics. There was no significant difference in treatment persistence between the two groups (p=0.762). Conclusion: There is a poor rate of persistence in treatment among patients with schizophrenia, regardless of the class of antipsychotics received. Considering the negative consequences of non-persistence in treatment including increased risk of relapse, re-hospitalisation and suicide, there is a dire need for interventions to facilitate treatment persistence in schizophrenia.
Authors and Affiliations
Increase Ibukun Adeosun
Keywords
Related Articles
- EP ID EP342436
- DOI 10.9734/BJPR/2016/23826
- Views 106
- Downloads 0
Anti-inflammatory, Antiarthritic and Antinociceptive Activities of 3,5-Disubstituted Thiazolidine Derivatives
Aims: The aim of this study was to investigate the anti-inflammatory, antiarthritic and antinociceptive effects of two thiazolidinedione derivatives: 3-(2-bromo-benzyl)-5-(4-methylsufonyl-benzylidene)-thiazolidine-2,4-di...
Comparative Study of the Physical Characteristics of Some Commercially Available Brands of Amoxicillin Capsules
Aim: To assess the quality of 10 brands of Amoxicillin Trihydrate 500 mg capsules. Study Design: Experimental. Place and Duration of Study: Experimental drugs were purchased from pharmacy in Okada and Benin and experime...
Antidepressant-like Activity of Celastrus paniculatus Seed Oil in Mice Subjected to Chronic Unpredictable Mild Stress
Aims: The present study was done to evaluate the antidepressant-like effect of Celastrus paniculatus seed oil in Swiss young albino mice subjected to chronic unpredictable mild stress. Study Design: Prospective. Place an...
Effect of Levetiracetam in the Treatment of Refractory Seizure in Infants through EEG: The Case of the Neonatal Intensive Care Unit of Tehran’s Children’s Medical Center
Objective: Phenobarbital, phenytoin and Benzodiazepins are the most common treatments for resistant neonatal seizure [1]. Drug of choice in the treatment of neonatal seizure should be more effective and have fewer side e...
The Protective Effect of Calcitriol on Diabetic Neuropathy in STZ-induced Diabetic Rats
Diabetic peripheral neuropathy (DPN) is one of the diabetic complications that have a complex etiology and even with good glycemic control can have severe consequences. To date, there is no effective treatment for DPN. T...